Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded in 1983, OSI Pharmaceuticals is a research-driven biotechnology company focused on the discovery, development and commercialisation of innovative products for the treatment of cancer. OSI had also developed selected opportunities arising from its extensive research and development programmes. However, on 24th October 2002, OSI announced that it is refocusing its entire business and R&D activities into the oncology arena. As a result, the company has reduced its overall headcount by approximately 40 people in the discovery research area, primarily in biology sciences. OSI intends to divest its non-oncology research assets, principally through an establishment of an externally-funded affiliated entity in the metabolic disease area.